A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer
The combination of paclitaxel and lapatinib was safe and demonstrated an efficacy signal. The RP2D was weekly paclitaxel 80 mg/m<sup>2</sup> combined with lapatinib 2000 mg twice daily two days before the paclitaxel dose. This trial was registered at ClinicalTrials.gov ID: NCT04608409.
Authors
- Donglin Yan (ORCID: https://orcid.org/0000-0002-5111-9437)
- Lauren Baldwin (ORCID: https://orcid.org/0000-0001-5180-9537)
- Connie D. Cao (ORCID: https://orcid.org/0000-0003-1408-210X)
- Frederick R. Ueland (ORCID: https://orcid.org/0000-0003-1213-7509)
- Dava Piecoro
- Rani Jayswal
- Hoda Saghaeiannejad Esfahani
- Christopher P. DeSimone
- Joseph Robert McCorkle
- Jill M. Kolesar
- Ning Li
- Rachel W. Miller
- Charles S. Dietrich
Institutions
- University of Iowa (US)
- University of Kentucky (US)
- Markey Cancer Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-14
- DOI
- https://doi.org/10.3390/cancers18040626
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00